Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus
2012-003859-12Phase 3Terminated
- Sponsor
- RWTH Aachen University
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and vasculitis comparing Linagliptin arm with Placebo arm (2 arms). Primary endpoint: Change in carotid FDG uptake. Started Apr 2013; status: terminated.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)vasculitis
Beyond the preview
Go deeper on 2012-003859-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003859-12.